Humana Inc.
HUM · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.51 | -2.40 | -8.91 | -1.93 |
| FCF Yield | 7.82% | 5.25% | 5.35% | 1.58% |
| EV / EBITDA | 11.97 | 13.28 | 14.71 | 15.66 |
| Quality | ||||
| ROIC | 6.84% | 5.27% | 6.22% | 9.26% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 2.44 | 1.60 | 1.64 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.24% | 8.59% | 6.37% | 8.58% |
| Free Cash Flow Growth | -19.68% | -14.13% | 266.49% | -79.76% |
| Safety | ||||
| Net Debt / EBITDA | 2.84 | 1.45 | 1.26 | 2.07 |
| Interest Coverage | 4.18 | 6.86 | 8.90 | 10.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8.38 | 6.98 | 6.58 | 7.97 |